نتائج البحث - "Ciardiello F."

1

مؤتمر

Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data from the EVEREST study

المؤلفون: Humblet, Y, Peeters, M, Gelderblom, H, Vermorken, JB, Viret, F, Glimelius, B, Ciardiello, F, Gallerani, E, Kisker, O, Van Cutsem, E

المصدر: EJC SUPPLEMENTS. 5(4):240-240

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:116411291Test

2

دورية أكاديمية

6566 A multicenter phase II study of induction CT with Folfox-4 and Cetuximab followed by RT and Cetuximab in locally advanced esophageal cancer (LAEC).

المؤلفون: De Vita, F., Vecchione, L., Orditura, M., Innocente, R., Farella, A., Morgillo, F., Pinto, C., Sileni, V. Chiarion, Ruol, A., Ciardiello, F.

المصدر: EJC Supplements; Jun2009, Vol. 7 Issue 2, p380-380, 1p

3

دورية أكاديمية

6565 The role of PET-TC in predicting the pCR in locally-advanced esophageal cancer (LAEC) after a preoperative CT-RT treatment: data from B152 trial.

المؤلفون: Vecchione, L., De Vita, F., Farella, A., Martinelli, E., Orditura, M., Innocente, R., Pinto, C., Sileni, V. Chiarion, Ciardiello, F., Troiani, T.

المصدر: EJC Supplements; Jun2009, Vol. 7 Issue 2, p380-380, 1p

4

دورية أكاديمية

6550 Adjuvant chemoradiation in stage III-IV radically resected gastric cancer patients: a pilot study.

المؤلفون: Orditura, M., Martinelli, E., De Vita, F., Galizia, G., Muto, P., Vitiello, F., Romano, A., Troiani, T., Morgillo, F., Ciardiello, F.

المصدر: EJC Supplements; Jun2009, Vol. 7 Issue 2, p376-376, 1p

5

دورية أكاديمية

1223 A model of synergistic antitumour activity of sorafenib, a multikinase inhibitor of Raf, VEGF and PDGF receptors, with anti-EGFR inhibitors (cetuximab and erlotinib) in a panel of colorectal and lung cancer cell lines.

المؤلفون: Martinelli, E., Troiani, T., Morgillo, F., Vecchione, L., Orditura, M., De Vita, F., Rodolico, G., Berrino, L., Ciardiello, F.

المصدر: EJC Supplements; Jun2009, Vol. 7 Issue 2, p127-127, 1p

6

دورية أكاديمية

1221 Enhanced sensitivity to Bortezomib pro apoptotic effects in human cancer cells with acquired resistance to anti-EGFR TKIs.

المؤلفون: Morgillo, F., Cantile, F., Fasano, M., Troiani, T., Martinelli, E., Vecchione, L., Orditura, M., De Vita, F., Ciardiello, F.

المصدر: EJC Supplements; Jun2009, Vol. 7 Issue 2, p126-126, 1p

7

دورية أكاديمية

280 Use of biologics in drug development.

المؤلفون: Morgillo, F., Ciardiello, F.

المصدر: EJC Supplements; Jun2009, Vol. 7 Issue 2, p67-67, 1p

8

دورية أكاديمية

3040 POSTER Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) with metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules.

المؤلفون: Ciardiello, F., Cervantes, A., Vega-Villegas, M., Casado, E., Rodriguez-Braun, E., Martinelli, E., Rojo, F., Baselga, J., Kisker, O., Tabernero, J.

المصدر: EJC Supplements; Aug2007, Vol. 5 Issue 4, p247-247, 1p

9

دورية أكاديمية

3017 POSTER Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data from the EVEREST study.

المؤلفون: Humblet, Y., Peeters, M., Gelderblom, H., Vermorken, J.B., Viret, F., Glimelius, B., Ciardiello, F., Gallerani, E., Kisker, O., van Cutsem, E.

المصدر: EJC Supplements; Aug2007, Vol. 5 Issue 4, p240-240, 1p

10

دورية أكاديمية

3001 ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC).

المؤلفون: van Cutsem, E., Bodoky, G., Kyung Roh, J., Folprecht, G., Park, Y.S., van Laethem, J.L., Raoul, J.L., Ciardiello, F., Lebrun, P., Rougier, P.

المصدر: EJC Supplements; Aug2007, Vol. 5 Issue 4, p235-235, 1p

تنقيح النتائج